Managing Director and Senior Equity Research Analyst at Canaccord Genuity
Kyle Mikson is a Managing Director and Senior Equity Research Analyst at Canaccord Genuity, specializing in Life Science Tools and Diagnostics with extensive coverage of companies engaged in genomics, molecular diagnostics, bioprocessing, liquid biopsy, and spatial biology. His coverage universe has included firms such as Pacific Biosciences, Natera, and Guardant Health, and while historically 26% of his stock ratings have outperformed with a most notable call delivering a 644% return on Pacific Biosciences, his recent one-year average return stands at -17.2%. Mikson began his research analyst career after industry finance roles at Express Scripts and joined Canaccord Genuity in 2021, where he has since advanced to Managing Director amid ongoing contributions to sector research. He holds a BS in Biomedical Engineering from Case Western Reserve University and is a CFA Charterholder.
Asked about the level of detail to be provided on safety data in the upcoming readout and the specific safety expectations and potential limitations for the highest dose being tested.
The company confirmed they will release top-line safety data, including adverse events. They expect the highest dose to have a safety profile similar to what was seen in the previous COMFORT study, which they consider very acceptable and consistent.
Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.
Trusted by leading investment firms and analysts